The clinical analysis of Takayasu's arteritis with pulmonary hypertension
10.3760/cma.j.issn.1007-7480.2009.09.008
- VernacularTitle:大动脉炎合并肺动脉高压患者的临床分析
- Author:
Jinzhi LAI
;
Dong XU
;
Mengtao LI
;
Zhuang TIAN
;
Shuyang ZHANG
;
Quan FANG
;
Xiaofeng ZENG
- Publication Type:Journal Article
- Keywords:
Takayasu's arteritis;
Hypertension,pulmonary;
Therapy
- From:
Chinese Journal of Rheumatology
2009;13(9):612-615
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical characteristics of Takayasu's arteritis (TA) with pulmonary hypertension (PAH) in order to improve the diagnosis and treatment earlier. Methods Twelve out of 191 patients with TA registered in Peking Union Medical College Hospital from 1987 to 2007 were diagnosed as PAH, the clinical data of 12 patients were analyzed. Results Ten patients were females. The range of age were from 14 to 47 years old, the average age was (27±10) years old. Eleven patients had the clinical manifestations or/and signs of pulmonary artery involvement. Seven patients presented with short breath after exercise or hemoptysis as the first manifestation, four patients with fatigue, four patients with intermittent claudication or pain or numbness of extremities, three patients with dizziness. Seven patients belonged to type Ⅰ+Ⅳ, one patient to type Ⅱ+Ⅳ, three patients to type Ⅲ+Ⅳ, one patient to type Ⅴ. Elevated ESR/CRP was found in ten patients. All patients took the glucocorticoid and DMARDs, stent implantation in pulmonary artery was done in one patient, Bentall was operated in another patient.The symptoms of all patients improved except one patient died for low cardiac output after operation. Conclusion PAH is one of the severe complications in late stage of TA, and other arteries are usually involved too. Because it is difficult to observe PAH in TA patients in early stage, CTA or pulmonary angiography and UCG should be taken in early stage. The stent implantation or dilating the artery should be considered aa a treatment, but at on the same time, glucocorticoid and DMARDs should be taken to avoid the relapse.
